http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114032308-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-686 |
| filingDate | 2021-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114032308-B |
| titleOfInvention | Use of FAM83A, KPNA2, KRT6A and LDHA in combination as biomarkers for lung adenocarcinoma |
| abstract | The invention belongs to the field of biomedicine, and discloses the use of FAM83A, KPNA2, KRT6A and LDHA gene combination as a lung adenocarcinoma biomarker. The invention also discloses the use of the substance for detecting FAM83A, KPNA2, KRT6A and LDHA in the preparation of the kit. The present invention uses FAM83A, KPNA2, KRT6A and LDHA as biomarkers for joint detection, provides an ideal expression profile analysis strategy, and a new combined biomarker kit for risk assessment and prognosis analysis of lung adenocarcinoma, which can be used It is effectively used in the diagnosis or prognosis evaluation of lung adenocarcinoma, and has a good clinical application prospect. |
| priorityDate | 2021-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.